June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization
Author Affiliations & Notes
  • Joao J Nassaralla
    Retina and Vitreous, Instituto de Olhos de Goiania and UnB, Goiania, Brazil
  • João Jorge Nassaralla
    Medicina, UFG, Goiania, Brazil
  • Belquiz A Nassaralla
    Cornea and Refractive Surgery, IOG, Goiania, Brazil
  • Arthur Amaral Nassaralla
    Medicina, Faculdade São Leopoldo Mandic, Campinas, Brazil
  • Footnotes
    Commercial Relationships Joao Nassaralla, None; João Jorge Nassaralla, None; Belquiz Nassaralla, None; Arthur Nassaralla, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4622. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joao J Nassaralla, João Jorge Nassaralla, Belquiz A Nassaralla, Arthur Amaral Nassaralla; Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4622.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To evaluate the clinical results of aflibercept intravitreal injection (AI) in choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV).


30 patients with subfoveal PM-CNV, were treated with 2 mg (0.05 mL or 50 microliters) AI. ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed. RII were repeated only in case of persistent angiographic leakage and if OCT scans showed retinal thickening or edema and serous retinal detachment. The follow-up period was at least 1 year.


The mean age of the study patients was 32 years (25-48) and the mean refractive error -11.50 D. At 12 months post-treatment, mean VA increased from 20/100 (20/400 -20/40) to 20/50 (20/200-20/30). Only 3 patients lost 35 letters due to macular atrophy; the other 27 increased or stabilized their VA. Mean macular thickness decreased from 329 to 258 µm. No ocular or general side effects were recorded.


These short-term results suggest that AI are effective and safe in patients with PM-CNV. The number of patients in this pilot study was limited and the follow-up is too short to make any specific treatment recommendations, but the favorable short-term results suggest further study is needed.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.